Pendjer I, Krejovic B, Vucicevic S
Institute of Otorhinolaryngology and Maxillofacial Surgery, Clinical Center of Serbia, Belgrade, Yugoslavia.
Eur Arch Otorhinolaryngol. 1997;254 Suppl 1:S127-9. doi: 10.1007/BF02439742.
Undifferentiated nasopharyngeal carcinoma has been related to the Epstein-Barr virus. These tumors are known to be radiosensitive and chemosensitive. While radiotherapy (RT) allows for a high rate of local control, 80% of all patients die from or with metastatic spread. This study analyzed 61 patients treated with RT alone and 28 treated with zorubicin (ZRB)-cisplatin (CDDP) and RT between 1977 and 1990. All patients treated with RT received 60-74 Gy in 6-7 weeks. Patients treated with combined therapy received ZRB 250 mg/m2 on the 1st day and CDDP 30 mg/m2 from the 2nd to 5th day. The interval between cycles was 4 weeks. Following treatment with chemotherapy patients were then given RT. The 5-year survival rate was 20% for patients with T1 and T2 tumors when treated with RT alone and 54% when treated with chemotherapy (CT). This was 25% for T3 and T4 lesions with RT only and 27% for RT with CT. Survival of patients with N0 and N1 lesions was 41% after RT and 60% after RT with CT. This decreased to 10% for N2 and N3 lesions treated with RT and 30% with RT and CT.
未分化鼻咽癌与EB病毒有关。已知这些肿瘤对放疗和化疗敏感。虽然放射治疗（RT）能实现较高的局部控制率，但所有患者中有80%死于或伴有转移扩散。本研究分析了1977年至1990年间61例单纯接受放疗的患者以及28例接受柔红霉素（ZRB）-顺铂（CDDP）联合放疗的患者。所有接受放疗的患者在6至7周内接受60 - 74 Gy的剂量。接受联合治疗的患者在第1天接受柔红霉素250 mg/m²，从第2天至第5天接受顺铂30 mg/m²。周期之间的间隔为4周。化疗后患者再接受放疗。T1和T2期肿瘤患者单纯放疗的5年生存率为20%，化疗（CT）治疗时为54%。T3和T4期病变单纯放疗时为25%，放疗联合化疗时为27%。N0和N1期病变患者放疗后的生存率为41%，放疗联合化疗后为60%。N2和N3期病变单纯放疗时生存率降至10%，放疗联合化疗时为30%。
